Efficient <i>in vitro</i> assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.

ABSTRACT: Novel and repurposed antiviral drugs are available for the treatment of coronavirus disease 2019 (COVID-19). However, antiviral combinations may be more potent and lead to faster viral clearance, but the methods for screening antiviral combinations against respiratory viruses are not well established and labor-intensive. Here, we describe a time-efficient (72-96 h) and simple in vitro drug-sensitivity assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using standard 96-well plates. We employ different synergy models (zero interaction potency, highest single agent, Loewe, Bliss) to determine the efficacy of antiviral therapies and synergistic combinations against ancestral and emerging clinical SARS-CoV-2 strains. We found that monotherapy of remdesivir, nirmatrel

SUBMITTER: Woodall M 

PROVIDER: S-EPMC11823597 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature